Consolidated segment reporting
All figures are reported excluding the discontinued operations of Fresenius Vamed, except for net income.
|
|
Fresenius Kabi |
|
Fresenius Helios |
|
Corporate/Other |
|
Fresenius Group |
||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
€ in millions |
|
20241 |
|
20231 |
|
Growth |
|
20241 |
|
20231 |
|
Growth |
|
20242 |
|
20232 |
|
Growth |
|
2024 |
|
2023 |
|
Growth |
||||||||||
Revenue |
|
8,414 |
|
8,009 |
|
5% |
|
12,739 |
|
11,952 |
|
7% |
|
680 |
|
1,106 |
|
-39% |
|
21,833 |
|
21,067 |
|
4% |
||||||||||
thereof contribution to consolidated revenue |
|
8,362 |
|
7,961 |
|
5% |
|
12,730 |
|
11,928 |
|
7% |
|
741 |
|
1,178 |
|
-37% |
|
21,833 |
|
21,067 |
|
4% |
||||||||||
thereof intercompany revenue |
|
52 |
|
48 |
|
8% |
|
9 |
|
24 |
|
-63% |
|
-61 |
|
-72 |
|
15% |
|
– |
|
– |
|
|
||||||||||
contribution to consolidated revenue |
|
38% |
|
38% |
|
|
|
58% |
|
57% |
|
|
|
4% |
|
5% |
|
|
|
100% |
|
100% |
|
|
||||||||||
EBITDA |
|
1,875 |
|
1,634 |
|
15% |
|
1,805 |
|
1,695 |
|
6% |
|
-694 |
|
-590 |
|
-18% |
|
2,986 |
|
2,739 |
|
9% |
||||||||||
Depreciation and amortization |
|
556 |
|
489 |
|
14% |
|
517 |
|
505 |
|
2% |
|
131 |
|
562 |
|
-77% |
|
1,204 |
|
1,556 |
|
-23% |
||||||||||
EBIT |
|
1,319 |
|
1,145 |
|
15% |
|
1,288 |
|
1,190 |
|
8% |
|
-825 |
|
-1,152 |
|
28% |
|
1,782 |
|
1,183 |
|
51% |
||||||||||
Net interest |
|
-130 |
|
-128 |
|
-2% |
|
-270 |
|
-235 |
|
-15% |
|
-32 |
|
-35 |
|
9% |
|
-432 |
|
-398 |
|
-9% |
||||||||||
Income taxes |
|
-284 |
|
-215 |
|
-32% |
|
-236 |
|
-243 |
|
3% |
|
-1 |
|
-27 |
|
96% |
|
-521 |
|
-485 |
|
-7% |
||||||||||
Noncontrolling interests |
|
-52 |
|
-54 |
|
4% |
|
-10 |
|
-7 |
|
-43% |
|
96 |
|
171 |
|
-44% |
|
34 |
|
110 |
|
-69% |
||||||||||
Income from Fresenius |
|
n.a. |
|
n.a. |
|
|
|
n.a. |
|
n.a. |
|
|
|
38 |
|
-959 |
|
104% |
|
38 |
|
-959 |
|
104% |
||||||||||
Net income from discontinued Fresenius Vamed operations |
|
n.a. |
|
n.a. |
|
|
|
n.a. |
|
n.a. |
|
|
|
-430 |
|
-45 |
|
-- |
|
-430 |
|
-45 |
|
-- |
||||||||||
Net income attributable to shareholders of Fresenius SE & Co. KGaA |
|
853 |
|
748 |
|
14% |
|
772 |
|
705 |
|
10% |
|
-1,154 |
|
-2,047 |
|
44% |
|
471 |
|
-594 |
|
179% |
||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Operating cash flow |
|
1,178 |
|
1,015 |
|
16% |
|
1,575 |
|
1,244 |
|
27% |
|
-306 |
|
-128 |
|
-139% |
|
2,447 |
|
2,131 |
|
15% |
||||||||||
Cash flow before acquisitions and dividends |
|
798 |
|
572 |
|
40% |
|
1,061 |
|
691 |
|
54% |
|
-236 |
|
-133 |
|
-77% |
|
1,623 |
|
1,130 |
|
44% |
||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Assets excl. Fresenius |
|
16,594 |
|
16,007 |
|
4% |
|
22,192 |
|
23,068 |
|
-4% |
|
1,125 |
|
2,709 |
|
-58% |
|
39,911 |
|
41,784 |
|
-4% |
||||||||||
Fresenius Medical Care investment accounted for using the equity method |
|
n.a. |
|
n.a. |
|
|
|
n.a. |
|
n.a. |
|
|
|
3,639 |
|
3,500 |
|
4% |
|
3,639 |
|
3,500 |
|
4% |
||||||||||
Debt |
|
3,568 |
|
3,684 |
|
-3% |
|
7,269 |
|
8,214 |
|
-12% |
|
2,740 |
|
3,932 |
|
-30% |
|
13,577 |
|
15,830 |
|
-14% |
||||||||||
Other operating liabilities |
|
4,004 |
|
3,711 |
|
8% |
|
3,573 |
|
4,071 |
|
-12% |
|
1,479 |
|
1,490 |
|
-1% |
|
9,056 |
|
9,272 |
|
-2% |
||||||||||
Capital expenditure, gross |
|
395 |
|
451 |
|
-12% |
|
517 |
|
573 |
|
-10% |
|
48 |
|
112 |
|
-57% |
|
960 |
|
1,136 |
|
-15% |
||||||||||
Acquisitions, gross / investments |
|
50 |
|
207 |
|
-76% |
|
7 |
|
0 |
|
|
|
18 |
|
3 |
|
-- |
|
75 |
|
210 |
|
-64% |
||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Research and development expenses |
|
631 |
|
604 |
|
4% |
|
3 |
|
3 |
|
0% |
|
7 |
|
54 |
|
-87% |
|
641 |
|
661 |
|
-3% |
||||||||||
Employees (per capita on balance sheet date) |
|
41,586 |
|
43,269 |
|
-4% |
|
128,558 |
|
129,439 |
|
-1% |
|
6,342 |
|
21,157 |
|
-70% |
|
176,486 |
|
193,865 |
|
-9% |
||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Key figures |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
EBITDA margin |
|
22.3% |
|
20.4% |
|
|
|
14.2% |
|
14.2% |
|
|
|
|
|
|
|
|
|
16.8%1 |
|
16.3%1 |
|
|
||||||||||
EBIT margin |
|
15.7% |
|
14.3% |
|
|
|
10.1% |
|
10.0% |
|
|
|
|
|
|
|
|
|
11.6%1 |
|
11.2%1 |
|
|
||||||||||
Depreciation and amortization in % of revenue |
|
6.6% |
|
6.1% |
|
|
|
4.1% |
|
4.2% |
|
|
|
|
|
|
|
|
|
5.2%1 |
|
5.2%1 |
|
|
||||||||||
Operating cash flow in % of revenue |
|
14.0% |
|
12.7% |
|
|
|
12.4% |
|
10.4% |
|
|
|
|
|
|
|
|
|
11.4%1 |
|
10.5%1 |
|
|
||||||||||
ROIC |
|
8.0% |
|
7.3% |
|
|
|
5.8% |
|
5.4% |
|
|
|
|
|
|
|
|
|
6.2%3 |
|
5.2%3 |
|
|
||||||||||
|
||||||||||||||||||||||||||||||||||